Skip to Content
 

News: Breast Cancer

Macara named ‘Pink Tie Guy’ for Komen breast cancer research

Thursday, January 11th, 2018

Ian Macara, PhD, Louise B. McGavock Professor and Chair of Cell and Developmental Biology and co-leader of the Signal Transduction and Chemical Biology Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the Pink Tie Guys for the Susan G. Komen Central Tennessee organization.

Mathis strives to make her cancer journey meaningful

Thursday, November 9th, 2017

Amanda Mathis went from being a patient at Vanderbilt-Ingram Cancer Center to becoming a member of the cancer center’s Board of Overseers.

New faculty profile: Tuya Pal, M.D.

Friday, October 27th, 2017

Tuya Pal, M.D., associate professor of medicine and Ingram Associate Professor of Cancer Research., specializes in cancer genetics and health disparities among diverse populations.

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

VICC investigators land support from Komen Foundation

Tuesday, October 3rd, 2017

Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.

Are you a breast cancer survivor?

Friday, September 22nd, 2017

Health & Wellness would like to celebrate you and support breast cancer awareness by creating an “Awareness Saves Lives” faculty and staff survivor banner. The banner will be displayed as part of the 2017 Breast Cancer Awareness Expo scheduled for Oct. 4 from 11 a.m. to 1 p.m. in the Light Hall North Lobby.

Breast Cancer Genomic Profiling Reveals Clues to Treatment Resistance

Friday, August 11th, 2017

Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers. Carlos L. Arteaga, M.D. More than 40,000 American women will die from breast […]

Stress may switch on bone “mets”

Friday, August 11th, 2017

Stress stimulates the formation of blood vessels in bone and may help breast cancer cells to invade this organ. In the July issue of the Journal of Bone and Mineral Research, Florent Elefteriou, Ph.D., Julie A. Sterling, Ph.D., and colleagues describe a mechanism for skeletal colonization by breast cancer cells that could lead to new ways to […]

Investigators match novel cancer mutations with potential therapies

Monday, August 7th, 2017

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]

Drivers of breast cancer metastasis

Thursday, July 27th, 2017

Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.D., and colleagues have now […]

Next Page »